Drug delivery systems provider, Aptar Pharma, will be launching its new portable respiratory device at CPhI worldwide, later this year.
The company will be showcasing its PureHale device, a drug delivery device designed for upper respiratory care.
Besides from its latest product release, Aptar Pharma will also be revealing a range of new connected drug delivery devices designed to increase dose adherence and improve patient outcomes; a portfolio of gamma-sterilised drug delivery components; and a support services initiative to help customers get their molecules to market.
Guillaume Brouet, vice president Analytical, Regulatory and Scientific Affairs at Aptar Pharma, said: “Through a wide range of consulting and services, Aptar Pharma innovates around delivery routes, effective drug delivery, testing and regulatory requirements with partners ranging from small-scale R&D firms to the largest international pharmaceutical companies. We look forward to launching our Support Services initiative at CPhI, and working with our customers to meet their development needs.”
Three Aptar Pharma executives will also be delivery Pharma Insight Briefings at the show, outlining the latest trends, technology and product innovations.
Lastly, the company will be showcasing its portfolio of drug delivery devices that address and range of conditions, as well as new solutions in prescriptions and over-the-counter treatments.
CPhI worldwide runs from 9-11 October, Madrid. Aptar Pharma will be exhibiting at stand 4D10.